[go: up one dir, main page]

FI931203A - CARBOXYLSYRAESTRAR AV RAPAMYCIN - Google Patents

CARBOXYLSYRAESTRAR AV RAPAMYCIN Download PDF

Info

Publication number
FI931203A
FI931203A FI931203A FI931203A FI931203A FI 931203 A FI931203 A FI 931203A FI 931203 A FI931203 A FI 931203A FI 931203 A FI931203 A FI 931203A FI 931203 A FI931203 A FI 931203A
Authority
FI
Finland
Prior art keywords
carboxylsyraestrar
rapamycin
Prior art date
Application number
FI931203A
Other languages
Finnish (fi)
Other versions
FI931203A0 (en
Inventor
Craig Eugene Caufield
Amedeo Arturo Failli
Robert John Steffan
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/657,294 external-priority patent/US5130307A/en
Application filed by American Home Prod filed Critical American Home Prod
Publication of FI931203A0 publication Critical patent/FI931203A0/en
Publication of FI931203A publication Critical patent/FI931203A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI931203A 1990-09-19 1993-03-18 CARBOXYLSYRAESTRAR AV RAPAMYCIN FI931203A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58483390A 1990-09-19 1990-09-19
US58987890A 1990-09-28 1990-09-28
US07/657,294 US5130307A (en) 1990-09-28 1991-02-19 Aminoesters of rapamycin
PCT/US1991/006824 WO1992005179A1 (en) 1990-09-19 1991-09-19 Carboxylic acid esters of rapamycin

Publications (2)

Publication Number Publication Date
FI931203A0 FI931203A0 (en) 1993-03-18
FI931203A true FI931203A (en) 1993-03-18

Family

ID=27416444

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931203A FI931203A (en) 1990-09-19 1993-03-18 CARBOXYLSYRAESTRAR AV RAPAMYCIN

Country Status (9)

Country Link
EP (1) EP0549727A1 (en)
JP (1) JPH06501012A (en)
AU (1) AU653175B2 (en)
FI (1) FI931203A (en)
HU (1) HUT65763A (en)
IE (1) IE913302A1 (en)
MX (1) MX9101139A (en)
PT (1) PT98990A (en)
WO (1) WO1992005179A1 (en)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427680B1 (en) * 1989-11-09 1995-08-23 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
NO921449L (en) * 1991-04-17 1992-10-19 American Home Prod CARBAMATES OF RAPAMYCIN
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
ES2258763T3 (en) * 1992-10-13 2006-09-01 Wyeth RAPAMYCINE CARBAMATES.
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
GB9307491D0 (en) * 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
AU6711994A (en) * 1993-04-23 1994-11-21 American Home Products Corporation Rapamycin conjugates and antibodies
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
ES2176245T3 (en) 1993-04-23 2002-12-01 Wyeth Corp OPEN CYCLE RAMAPICIN ANTIBODIES.
JP4105761B2 (en) * 1993-11-19 2008-06-25 アボット・ラボラトリーズ Semi-synthetic analog immunomodulator of rapamycin (macrolide)
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
DK0734389T3 (en) * 1993-12-17 2000-08-21 Novartis Ag Rapamycin derivatives useful as immunosuppressants
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
CN1124276C (en) * 1995-06-09 2003-10-15 诺瓦蒂斯有限公司 Rapamycin derivatives
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US8057816B2 (en) 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US7378105B2 (en) 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US8257726B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8394398B2 (en) 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US7357942B2 (en) 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE60012192T2 (en) * 1999-08-18 2005-09-08 Wyeth WATER-SOLUBLE SDZ-WHEEL ESTER
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
DE60136200D1 (en) * 2000-09-19 2008-11-27 Wyeth Corp WATER-SOLUBLE RAPAMYCIN ESTERS
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
CN100349627C (en) 2002-09-06 2007-11-21 艾博特公司 Medical devices containing rapamycin analogs
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
JP2007511203A (en) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション Diarylurea with kinase inhibitory activity
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
CN1942478A (en) * 2004-04-14 2007-04-04 惠氏公司 Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
SG152234A1 (en) * 2004-04-14 2009-05-29 Wyeth Corp Regiospecific synthesis of rapamycin 42-ester derivatives
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
MX2007010892A (en) 2005-03-07 2007-12-05 Wyeth Corp Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin.
JP5271697B2 (en) 2005-03-23 2013-08-21 アボット ラボラトリーズ Delivery of highly lipophilic drugs through medical devices
WO2007032777A2 (en) 2005-03-23 2007-03-22 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
AU2006271650B8 (en) 2005-07-20 2011-02-10 Novartis Ag Combination of a pyrimidylaminobenzamide and an mTOR kinase inhibitor
KR20080065704A (en) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 Medical Abnormal Treatment Methods, Compositions, and Kits
WO2007059311A2 (en) 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
DK2275103T3 (en) 2005-11-21 2014-07-07 Novartis Ag mTor inhibitors in the treatment of endocrine tumors
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US7622477B2 (en) 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
BRPI0709016A2 (en) 2006-03-23 2011-06-21 Macusight Inc formulations and methods for diseases or conditions related to vascular permeability
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
BRPI0719509A2 (en) 2006-09-28 2013-12-31 Follica Inc METHODS, KITS AND COMPOSITIONS FOR GENERATING NEW HAIR FOLICULES AND HAIR GROWTH
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
JP5134692B2 (en) 2007-12-19 2013-01-30 アボット・ラボラトリーズ Immunosuppressant drug extraction reagent for immunoassay
CA2711765A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US10485792B2 (en) 2009-08-26 2019-11-26 Hadasit Medical Research Services & Development Limited Sustained release delivery systems for the prevention and treatment of head and neck cancers
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
ES2689177T3 (en) 2010-04-13 2018-11-08 Novartis Ag Combination comprising a cyclin dependent kinase 4 inhibitor or cyclin dependent kinase (CDK4 / 6) and an mTOR inhibitor for treating cancer
MX2012012058A (en) 2010-04-16 2012-11-22 Novartis Ag Combination of organic compounds.
KR101253399B1 (en) 2010-10-26 2013-04-11 영남대학교 산학협력단 Rapamycin formulation encapsulated in reconstituted high-density lipoprotein containing V156K-apoA-I
CA3122934A1 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Fusion protein comprising a fragment of cd40 and method of producing same
NZ615593A (en) 2011-04-25 2015-05-29 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
KR20150010716A (en) 2012-03-23 2015-01-28 더 유니버시티 오브 퀸스랜드 Immunomodulatory Agent and Uses Therefor
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanoparticles for treatment of allergy
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS USEFUL FOR THE TREATMENT OF GLIOBLASTOMA
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR102233251B1 (en) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 Novel nanoparticle compositions
WO2014184734A1 (en) 2013-05-14 2014-11-20 Novartis Ag Markers associated with mtor inhibition
WO2014200659A1 (en) 2013-06-11 2014-12-18 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015044854A1 (en) 2013-09-24 2015-04-02 Novartis Ag Markers associated with mtor inhibition
AU2015216590A1 (en) 2014-02-11 2016-06-30 Novartis Ag Pharmaceutical combinations comprising a PI3K inhibitor for the treatment of cancer
US10300070B2 (en) 2014-03-27 2019-05-28 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
US10258639B2 (en) 2014-05-06 2019-04-16 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
CN105461738B (en) * 2014-06-03 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 A kind of rapamycin derivative, preparation method, its pharmaceutical composition and purposes
CN107073066B (en) 2014-09-11 2021-09-17 加利福尼亚大学董事会 mTORC1 inhibitors
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
JP6855470B2 (en) 2016-05-27 2021-04-07 日本化薬株式会社 Pharmaceutical composition containing rapamycin or a derivative thereof
US10668011B2 (en) 2016-06-30 2020-06-02 Durect Corporation Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
PT3558955T (en) 2016-12-22 2021-10-19 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
EA201990127A1 (en) 2016-12-30 2020-08-18 Дьюрект Корпорейшн DEPO-PREPARATION
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
CN111051306B (en) 2017-09-08 2023-01-03 美国安进公司 Inhibitors of KRAS G12C and methods of use thereof
CN112368289B (en) 2018-05-01 2024-02-20 锐新医药公司 C26-linked rapamycin analogues as MTOR inhibitors
KR20210018244A (en) 2018-05-01 2021-02-17 레볼루션 메디슨즈, 인크. C40-, C28- and C-32-linked rapamycin analogs as mTOR inhibitors
MA52496A (en) 2018-05-04 2021-03-10 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
MX2020010836A (en) 2018-05-04 2021-01-08 Amgen Inc Kras g12c inhibitors and methods of using the same.
MA52564A (en) 2018-05-10 2021-03-17 Amgen Inc KRAS G12C INHIBITORS FOR CANCER TREATMENT
EP3802535B1 (en) 2018-06-01 2022-12-14 Amgen, Inc Kras g12c inhibitors and methods of using the same
EP3802537A1 (en) 2018-06-11 2021-04-14 Amgen Inc. Kras g12c inhibitors for treating cancer
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
AU2019384118A1 (en) 2018-11-19 2021-05-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3897855B1 (en) 2018-12-20 2023-06-07 Amgen Inc. Kif18a inhibitors
JP2022513971A (en) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Heteroarylamide useful as a KIF18A inhibitor
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
BR112021011989A2 (en) 2018-12-20 2021-09-08 Amgen Inc. KIF18A INHIBITORS
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CA3130080A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
MX2021014126A (en) 2019-05-21 2022-01-04 Amgen Inc FORMS IN SOLID STATE.
EP4007756A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Kif18a inhibitors
CN114391012A (en) 2019-08-02 2022-04-22 美国安进公司 Pyridine derivatives as KIF18A inhibitors
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
JOP20220101A1 (en) 2019-10-28 2023-01-30 Merck Sharp & Dohme Small-molecule inhibitors of the G12C mutant Kirsten's rat sarcoma protein (KRAS)
US20230023023A1 (en) 2019-10-31 2023-01-26 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
CR20220240A (en) 2019-11-04 2022-08-03 Revolution Medicines Inc RAS INHIBITORS
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
PE20221278A1 (en) 2019-11-04 2022-09-05 Revolution Medicines Inc RAS INHIBITORS
EP4055017A1 (en) 2019-11-08 2022-09-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
EP4058453A1 (en) 2019-11-14 2022-09-21 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
JP2023505100A (en) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド Covalent RAS inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
IL294484A (en) 2020-01-07 2022-09-01 Revolution Medicines Inc Dosage for shp2 inhibitor and methods for treating cancer
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
EP4183395A4 (en) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
MX2023002248A (en) 2020-09-03 2023-05-16 Revolution Medicines Inc Use of sos1 inhibitors to treat malignancies with shp2 mutations.
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
BR112023022819A2 (en) 2021-05-05 2024-01-16 Revolution Medicines Inc COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATES AND METHODS FOR TREATING CANCER IN A SUBJECT, FOR TREATING A DISORDER AND FOR INHIBITING A RAS PROTEIN IN A CELL
JP2024517845A (en) 2021-05-05 2024-04-23 レボリューション メディシンズ インコーポレイテッド RAS Inhibitors for Cancer Treatment
CN117769554A (en) 2021-05-28 2024-03-26 大鹏药品工业株式会社 Small molecule inhibitors of KRAS muteins
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
TW202340214A (en) 2021-12-17 2023-10-16 美商健臻公司 Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN119136806A (en) 2022-03-08 2024-12-13 锐新医药公司 Method for treating immune refractory lung cancer
WO2023230577A1 (en) 2022-05-25 2023-11-30 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
IL317476A (en) 2022-06-10 2025-02-01 Revolution Medicines Inc Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
JPH04230389A (en) * 1990-07-16 1992-08-19 American Home Prod Corp Rapamycin derivative
JP3140228B2 (en) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 Novel macrocyclic lactone and its producing bacteria

Also Published As

Publication number Publication date
MX9101139A (en) 1992-05-04
FI931203A0 (en) 1993-03-18
HU9300776D0 (en) 1993-06-28
AU653175B2 (en) 1994-09-22
HUT65763A (en) 1994-07-28
JPH06501012A (en) 1994-01-27
EP0549727A1 (en) 1993-07-07
IE913302A1 (en) 1992-02-25
AU8659991A (en) 1992-04-15
WO1992005179A1 (en) 1992-04-02
PT98990A (en) 1992-08-31

Similar Documents

Publication Publication Date Title
FI931203A0 (en) CARBOXYLSYRAESTRAR AV RAPAMYCIN
FI921328A (en) SILYLETRAR AV RAPAMYCIN
FI930886A0 (en) FOERFARANDE FOER HINDRANDE AV AVSTOETNING AV TRANSPLANTERAD VAEVNAD
FI932336A0 (en) Inhibering av celladhesionprotein-kolhydratvaexelverkan
FI930848A0 (en) FOERFARANDE FOER SEPARERING AV ILMENIT
FI923931A (en) ANORDINATION FOR GRANSKNING AV INSIDAN AV EN FOERGRENAD ROERLINJE
FI931357A (en) FRAMSTAELLNING AV POLYHYDROXIFETTSYRAAMIDER I NAERVARO AV LOESNINGSMEDEL
FI930165A (en) FRAMSTAELLNING AV SYNNERLIGEN AKTIVA TVAETTMEDELSPARTIKLAR
FI931355A (en) FASOEVERFOERINGSMEDIERAT FOERFARANDE FOER FRAMSTAELLNING AV GLUKAMIDTVAETTMEDEL
FI931356A (en) FOERBAETTRAT KATALYTISKT FOERFARANDE FOER FRAMSTAELLNING AV GLUKAMIDTVAETTMEDEL
FI925805A (en) FRAMSTAELLNING AV KOMPOSITMATERIAL
FI925609A (en) FOERFARANDE FOER FRAMSTAELLNING AV SYKLISKA SULFATER
FI931879A0 (en) FRAMSTAELLNING AV EN PEROXOSYRA
FI923779A (en) FOERBAETTRINGAR I TILLVERKNINGEN AV NYLONGARN
FI931534A (en) Foerfarande Foer foerbaettring av aktiveringen av hydrauliskt masugns slagg Foer framstaellning av byggnadsmaterial
FI930034A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV AVLAONGT FOEREMAOL
FI925544A0 (en) BENSOESYRADERIVAT FOER BEHANDLING AV LEUKOTRIENASSOCIERADE SJUKDOMAR
FI925546A (en) AMIDKOPPLADE PYRIDYLBENSOESYRADERIVAT FOER BEHANDLING AV LEUKOTRIEN-ASSOCIERADE SJUKDOMAR
FI930013A0 (en) HORMONDERIVAT AV BAKRE HYPOFYSLOBEN
FI930123A0 (en) FOERFARANDE FOER ANVAENDNING AV OXIDERADE LIPOPROTEINER I VIRUSARTADE INFEKTIONER
FI923795A (en) KRETSELEMENT FOER AOSTADKOMMANDE AV EN SPAERRSPAENNING FOER KOPPLINSDIODER
FI932198A (en) Anordning Foer skydd av kondensorroer
FI932901A0 (en) Foerfarande Foer framstaellning av alkalimonofluorfosfat
FI924154A (en) FOERFARANDE FOER FRAMSTAELLNING AV PENEM-ESTRAR
FI88315C (en) FOERFARANDE FOER BLEKNING AV CELLULOSAMASSA

Legal Events

Date Code Title Description
FD Application lapsed